527. Lower Risk of ICU Admission with Remdesivir in Patients Hospitalized with COVID-19 Pneumonia

BACKGROUND: Remdesivir (RDV) was approved by FDA in October 2020 for use in hospitalized patients with COVID-19. We examined the association between RDV treatment and ICU admission in patients hospitalized with COVID-19 pneumonia requiring supplemental oxygen (but not advanced respiratory support) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sarah, Schreiner, Pamela, Lifson, Alan, Bye, Erica, Como-Sabetti, Kathryn, Lynfield, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644404/
http://dx.doi.org/10.1093/ofid/ofab466.726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644404/
http://dx.doi.org/10.1093/ofid/ofab466.726

Ejemplares similares